Hana Field: Okay, I have to tell you — I've been carrying this around since yesterday and I need to just say it out loud: a researcher overrode a woman's own account of how old she was. She said 104. The Gerontology Research Group had 113. They went with 113.
Iris Holm: That's in the MIT Press piece. Newman documents it.
Hana Field: Published October 13, 2026 — 'Longevity Research Has a Bullshit Problem' — adapted from his book 'Morbid.' And I keep thinking: that woman knew. She knew.
Iris Holm: Hold on — because that same day, the New York Times is running a piece citing the XRC Brand Capital Fund's 2026 report showing longevity web searches were four times higher in late 2025 than the year before. Peak hunger, peak doubt, one Tuesday.
Hana Field: That's the thing I can't resolve, and it's what this whole episode is actually about — why does public appetite for longevity science spike hardest at the exact moment its data is being called fraudulent?
Iris Holm: And Newman — Saul Justin Newman, Oxford, 2024 Ig Nobel Prize winner — his answer is basically: because the regions famous for producing 110-year-olds are also famous for terrible birth records and pension fraud. Which is uncomfortable.
Hana Field: Very uncomfortable, yeah — and the Ig Nobel part matters more than it sounds, because that award is specifically for research that makes you laugh first. So the most serious institutional critique of longevity science arrived wearing a clown nose.
Iris Holm: Which tells you exactly how the field decided to absorb it.
Hana Field: And that clown nose is exactly the mechanism, actually — because once the field absorbed Newman's critique as entertainment, it didn't have to reckon with what the critique was actually saying. Which is: a database is just a rumor that got written down. And once it's written down, the institution defends the rumor. Not the truth.
Iris Holm: The Gerontology Research Group defending 113 over the woman saying 104.
Hana Field: Right — and the researchers didn't go back and check. They published 113 as scientific fact because that's what their validated record said. The woman's own account of her own life was — it was just noise to the system. And that's not one case. Newman's whole argument is that supercentenarian claims above 110 rest on exactly this: poor birth records, no verification, and institutions that have built so much on top of those numbers that they can't afford to question them.
Iris Holm: So the Blue Zones. The Sardinian shepherds. The Okinawan elders. All of it built on the same floor?
Hana Field: Newman's analysis challenges the Blue Zones at their demographic foundation, yeah. The regions famous for producing centenarians are — and this is the uncomfortable part — also the regions with the worst birth registration infrastructure. So you can't actually separate the longevity claim from the record-keeping failure.
Iris Holm: Wait — so decades of health research. Diet, social cohesion, purpose. Built on headcount data that might be wrong.
Hana Field: And it's not just Newman saying it from outside. Dr. Sofiya Milman — she's at the Albert Einstein College of Medicine's Institute for Aging Research — she told the New York Times that most of what circulates in the longevity space is not science-based and needs to be dispelled. So you've got the internal credible voices saying the same thing the Ig Nobel winner is saying from the outside.
Iris Holm: That's not one contrarian. That's a pattern. So here's what I need you to answer — if the foundation is this compromised, what exactly has the field been building on top of it for thirty years?
Hana Field: That's the question that keeps me up, honestly. Because some of what sits on top — the lifestyle stuff, the exercise, the community — might still be real. But we don't actually know, because the data underneath was never clean enough to tell us what we were measuring.
Iris Holm: But here's where that stops being a philosophy problem. The Washington Post — same day, October 13, 2026 — is reporting people actually getting hurt. Dylan Meetze took an experimental intranasal peptide for three days. Three days. And ended up feeling, quote, 'underwater.' Couldn't function. Severe cognitive impairment.
Hana Field: Oh. Oh, that's — yeah, that lands differently than a migraine.
Iris Holm: Migraines, eye pain, fatigue — other cases in the same piece. And while the Post is publishing that, Robert F. Kennedy Jr., Health Secretary, is signaling he wants to loosen access to these same unregulated peptides. That's not drift. That's policy moving in the opposite direction from documented harm.
Hana Field: And I want to hold something here — because I think some of the people taking these compounds have already been through everything conventional medicine offered them. So the calculation isn't purely naive, you know? It's — what happens when someone decides the risk feels worth it because nothing else worked?
Iris Holm: That's real. But it doesn't close the question of who benefits from the vacuum staying open. Because YouTube and TikTok are flooded — no evidentiary bar, no oversight — and once a bad claim is circulating at that scale, it doesn't get dislodged.
Hana Field: No, it doesn't. And the person watching that TikTok isn't thinking about the investor behind the longevity startup. They're thinking — actually, no — they're not thinking at all. They're just scared, and it's eleven at night, and the alternative is sitting with the fact that nothing is guaranteed.
Iris Holm: Right. But fear doesn't make the regulatory vacuum accidental. Someone's interests are being served by keeping it open. The question is whether that someone is Dylan Meetze.
Hana Field: No. No, it's not.
Iris Holm: And the GLP-1 story is actually the exception — because that's the one case with real mechanistic promise, and Dr. Seamus O'Mahony's sweeping dismissal of the whole field may be getting that one wrong. We'll get there.
Hana Field: And that's where GLP-1 drugs land in this — because semaglutide is actually doing something mechanistically. CNN published on October 13, 2026, the same day as everything else, covering early-stage research into whether this class of drugs might have anti-aging properties beyond weight loss and blood sugar. Not fringe researchers. Real scientists, cautiously.
Iris Holm: Cautiously how?
Hana Field: The scientists quoted in that CNN piece are saying — and this is the honest version — the evidence is preliminary and largely from mice. Not humans. So the mechanistic rationale exists, and it's credible, but the human data isn't there yet.
Iris Holm: Okay. Mechanistic plausibility is not nothing. That's a real distinction.
Hana Field: It's a genuinely real distinction — and that's actually where Dr. Seamus O'Mahony's Telegraph piece becomes a problem, because he called longevity medicine broadly a pseudo-medical enterprise. Which, for the supercentenarian database stuff, for the unregulated peptides Dylan Meetze was taking — yeah, fair. But semaglutide isn't a basement compound. It has an actual mechanism. And a sweeping dismissal doesn't know how to make that cut.
Iris Holm: So O'Mahony's right about the fraud and takes out the real candidate in the same sentence.
Hana Field: And that's the structural irony that I find — I mean, it's almost brutal when you see it clearly. Because Newman's MIT Press critique says the field's evidentiary standards are too weak to trust. And he's documenting something real. But that credibility collapse doesn't stay contained. It poisons the atmosphere for everything inside the field's borders, including the things that might actually hold. So now imagine a researcher with solid mouse data on semaglutide trying to get a clean hearing in, I don't know, late 2026, when the loudest public story about longevity science is that it has a bullshit problem.
Iris Holm: The hype cycle runs both ways. It elevated the fraud, and now it's contaminating what's real.
Hana Field: Both directions, yeah — and the field built that. It chose not to police itself, and now even the one drug with genuine mechanistic promise can't step out of the wreckage cleanly.
Iris Holm: Newman wins the 2024 Ig Nobel. Book deal. MIT Press piece. And the search surge quadruples on the same October morning the critique lands. So what I can't actually answer — is that the beginning? Or is it the peak? The moment right before the whole thing tips over?
Hana Field: I don't know. And I think — actually, I'm not sure that question has a clean answer yet, because what would have to happen for it to be a beginning is that Newman's critique gets met with real reform. Not a book. Reform. How supercentenarian ages get collected, how the Gerontology Research Group validates records against what the person actually says. And there's no sign of that. None.
Iris Holm: So a year from now, if nothing in the data infrastructure changes — what are people Googling?
Hana Field: That's the one I'm left holding. And I don't want to answer it.
Iris Holm: Neither do I. That's probably the honest place this lands.
